Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Centessa Pharmaceuticals PLC tiene un precio objetivo de consenso de $29.93 basado en las calificaciones de 20 analistas. El máximo es $62, emitido por Oppenheimer el diciembre 10, 2025. El mínimo es $5, emitido por Goldman Sachs el agosto 15, 2023. Las 3 calificaciones de analistas más recientes fueron publicadas por Wells Fargo, Leerink Partners y Wolfe Research el abril 20, 2026, abril 1, 2026 y febrero 24, 2026, respectivamente. Con un precio objetivo promedio de $40.67 entre Wells Fargo, Leerink Partners y Wolfe Research, hay una 2.48% upside implícita para Centessa Pharmaceuticals PLC según estas calificaciones más recientes de analistas.
1calculado a partir de las calificaciones de los analistas
El último precio objetivo de Centessa Pharmaceuticals (NASDAQ:CNTA) fue comunicado por Wells Fargo el abril 20, 2026. La firma de analistas fijó un precio objetivo para $42.00 que espera CNTA a rise dentro de 12 meses (un posible 5.84% upside). 20 firmas de analistas han reportado calificaciones en el último año.
La última calificación de analistas para Centessa Pharmaceuticals (NASDAQ:CNTA) fue proporcionada por Wells Fargo, y Centessa Pharmaceuticals rebajado su equal-weight calificación.
La última revisión al alza de Centessa Pharmaceuticals PLC se produjo en septiembre 19, 2024, cuando Morgan Stanley elevó su precio objetivo a $26. Morgan Stanley anteriormente tenía an equal-weight para Centessa Pharmaceuticals PLC.
La última revisión a la baja de Centessa Pharmaceuticals PLC se produjo en abril 20, 2026, cuando Wells Fargo cambió su precio objetivo de $35 a $42 para Centessa Pharmaceuticals PLC.
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Centessa Pharmaceuticals, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Centessa Pharmaceuticals se registró el abril 20, 2026, por lo que la próxima calificación estará disponible en torno al abril 20, 2027.
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Centessa Pharmaceuticals (CNTA) fue un rebajado con un precio objetivo de $35.00 a $42.00. El precio actual al que cotiza Centessa Pharmaceuticals (CNTA) es de $39.68, que es within del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.
Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas
Datos de mercado proporcionados por APIs de Benzinga
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

| Buy Now | Get Alert | ||||||
|---|---|---|---|---|---|---|---|
| 04/20/2026 | Buy Now | 5.84% | Wells Fargo | $35 → $42 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 04/02/2026 | Buy Now | — | Guggenheim | — | Downgrade | Buy → Neutral | Get Alert |
| 04/01/2026 | Buy Now | 0.8% | Leerink Partners | $36 → $40 | Downgrade | Outperform → Market Perform | Get Alert |
| 03/31/2026 | Buy Now | — | Wolfe Research | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 03/31/2026 | Buy Now | — | Needham | — | Downgrade | Buy → Hold | Get Alert |
| 02/24/2026 | Buy Now | 0.8% | Wolfe Research | → $40 | Initiates | → Outperform | Get Alert |
| 01/29/2026 | Buy Now | -4.24% | Truist Securities | $33 → $38 | Maintains | Buy | Get Alert |
| 01/08/2026 | Buy Now | -16.84% | Truist Securities | $30 → $33 | Maintains | Buy | Get Alert |
| 01/02/2026 | Buy Now | -24.4% | Chardan Capital | $30 → $30 | Maintains | Buy | Get Alert |
| 12/10/2025 | Buy Now | 56.24% | Oppenheimer | $40 → $62 | Maintains | Outperform | Get Alert |
| 12/01/2025 | Buy Now | 5.84% | B. Riley Securities | $33 → $42 | Maintains | Buy | Get Alert |
| 11/18/2025 | Buy Now | 8.36% | Guggenheim | $28 → $43 | Maintains | Buy | Get Alert |
| 11/13/2025 | Buy Now | -11.8% | Wells Fargo | $30 → $35 | Maintains | Overweight | Get Alert |
| 11/07/2025 | Buy Now | -24.4% | Wells Fargo | $31 → $30 | Maintains | Overweight | Get Alert |
| 10/28/2025 | Buy Now | -11.8% | Stephens & Co. | → $35 | Initiates | → Overweight | Get Alert |
| 10/06/2025 | Buy Now | -29.44% | Guggenheim | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 09/03/2025 | Buy Now | -21.88% | Wells Fargo | → $31 | Initiates | → Overweight | Get Alert |
| 08/12/2025 | Buy Now | -24.4% | Chardan Capital | $30 → $30 | Maintains | Buy | Get Alert |
| 07/30/2025 | Buy Now | -24.4% | Chardan Capital | $30 → $30 | Maintains | Buy | Get Alert |
| 07/21/2025 | Buy Now | -24.4% | Truist Securities | → $30 | Initiates | → Buy | Get Alert |
| 05/28/2025 | Buy Now | -11.8% | Needham | → $35 | Initiates | → Buy | Get Alert |
| 05/08/2025 | Buy Now | -24.4% | Chardan Capital | → $30 | Initiates | → Buy | Get Alert |
| 03/31/2025 | Buy Now | -4.24% | Piper Sandler | → $38 | Initiates | → Overweight | Get Alert |
| 03/26/2025 | Buy Now | -29.44% | Guggenheim | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2025 | Buy Now | -31.96% | Morgan Stanley | $27 → $27 | Assumes | → Overweight | Get Alert |
| 02/10/2025 | Buy Now | — | Guggenheim | — | Reiterates | Buy → Buy | Get Alert |
| 01/07/2025 | Buy Now | — | TD Cowen | — | Initiates | → Buy | Get Alert |
| 11/15/2024 | Buy Now | -29.44% | Guggenheim | $24 → $28 | Maintains | Buy | Get Alert |
| 09/19/2024 | Buy Now | -34.48% | Morgan Stanley | $11 → $26 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 09/19/2024 | Buy Now | -16.84% | B. Riley Securities | → $33 | Initiates | → Buy | Get Alert |
| 09/16/2024 | Buy Now | -11.8% | BMO Capital | $20 → $35 | Maintains | Outperform | Get Alert |
| 09/11/2024 | Buy Now | -39.52% | Guggenheim | $20 → $24 | Maintains | Buy | Get Alert |
| 09/11/2024 | Buy Now | -52.12% | Jefferies | $13 → $19 | Maintains | Buy | Get Alert |
| 09/09/2024 | Buy Now | -49.6% | BMO Capital | $15 → $20 | Maintains | Outperform | Get Alert |
| 08/14/2024 | Buy Now | -64.72% | Oppenheimer | $14 → $14 | Reiterates | Outperform → Outperform | Get Alert |
| 07/18/2024 | Buy Now | -64.72% | Oppenheimer | → $14 | Initiates | → Outperform | Get Alert |
| 06/21/2024 | Buy Now | -72.28% | Morgan Stanley | $8 → $11 | Maintains | Equal-Weight | Get Alert |
| 04/01/2024 | Buy Now | -62.2% | BMO Capital | $15 → $15 | Maintains | Outperform | Get Alert |
| 11/15/2023 | Buy Now | -72.28% | Jefferies | $4 → $11 | Upgrade | Hold → Buy | Get Alert |
| 10/26/2023 | Buy Now | -79.84% | Morgan Stanley | $4 → $8 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 08/15/2023 | Buy Now | -72.28% | SVB Securities | $6 → $11 | Maintains | Outperform | Get Alert |
| 08/15/2023 | Buy Now | -74.8% | Guggenheim | $9 → $10 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | -87.4% | Goldman Sachs | $4.5 → $5 | Maintains | Neutral | Get Alert |
| 07/25/2023 | Buy Now | -62.2% | BMO Capital | $11 → $15 | Maintains | Outperform | Get Alert |
| 06/21/2023 | Buy Now | — | Evercore ISI Group | — | Initiates | → Outperform | Get Alert |
| 06/12/2023 | Buy Now | -77.32% | Guggenheim | → $9 | Initiates | → Buy | Get Alert |